CMMB vs. MTEM, ATHE, NCNA, GRTX, UPC, ADXN, AEZS, GHSI, MBRX, and MIRA
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Molecular Templates (MTEM), Alterity Therapeutics (ATHE), NuCana (NCNA), Galera Therapeutics (GRTX), Universe Pharmaceuticals (UPC), Addex Therapeutics (ADXN), Aeterna Zentaris (AEZS), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Molecular Templates (NASDAQ:MTEM) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
Molecular Templates has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Chemomab Therapeutics has a consensus price target of $5.67, suggesting a potential upside of 582.73%. Given Molecular Templates' higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Molecular Templates.
Molecular Templates has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks.
95.5% of Molecular Templates shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 13.4% of Molecular Templates shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Molecular Templates received 326 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 61.54% of users gave Chemomab Therapeutics an outperform vote.
In the previous week, Molecular Templates had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 5 mentions for Molecular Templates and 2 mentions for Chemomab Therapeutics. Molecular Templates' average media sentiment score of 0.40 beat Chemomab Therapeutics' score of -0.09 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.
Chemomab Therapeutics has a net margin of 0.00% compared to Chemomab Therapeutics' net margin of -57.92%. Molecular Templates' return on equity of -109.92% beat Chemomab Therapeutics' return on equity.
Summary
Molecular Templates beats Chemomab Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
